Overview

Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

This study will test the safety, tolerability and pharmacokinetics of single doses of ISIS 333611 administered into the spinal canal as 12 hour infusions.

Phase:

Phase 1

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.

Collaborators:

ALS Association
Muscular Dystrophy Association

Treatments:

Superoxide Dismutase